Sat . 19 May 2019

Oritavancin

oritavancin antibiotic, oritavancin
Oritavancin INN, also known as LY333328, Orbactiv is a novel semisynthetic glycopeptide antibiotic for the treatment of serious Gram-positive bacterial infections Its chemical structure as a lipoglycopeptide is similar to vancomycin

In August 2014, the United States FDA approved oritavancin for treatment of skin infections

Contents

  • 1 In vitro activity
    • 11 Mechanism
  • 2 Clinical trials
  • 3 History
  • 4 References
  • 5 External links

In vitro activity

Oritavancin shares certain properties with other members of the glycopeptide class of antibiotics, which includes vancomycin, the current standard of care for serious Gram-positive infections in the United States and Europe Oritavancin possesses potent and rapid bactericidal activity in vitro against a broad spectrum of both resistant and susceptible Gram-positive bacteria, including Staphylococcus aureus, MRSA, enterococci, and streptococci Oritavancin was more active than either metronidazole or vancomycin against strains of Clostridium difficile tested

Oritavancin has potential use as a therapy for exposure to Bacillus anthracis, the Gram-positive bacterium that causes anthrax, having demonstrated efficacy in a mouse model both before and after exposure to the bacterium

Mechanism

The 4'-chlorobiphenylmethyl group disrupts the cell membrane of Gram-positive bacteria It also acts by inhibition of transglycosylation and inhibition of transpeptidation

Clinical trials

In 2003 results were presented from two pivotal phase-III clinical trials testing the efficacy of daily intravenous oritavancin for the treatment of acute bacterial skin and skin-structure infections ABSSSI caused by Gram-positive bacteria The primary endpoints of both studies were met, with oritavancin achieving efficacy with fewer days of therapy than the comparator agents vancomycin followed by cephalexin Oritavancin showed a statistically significant improved safety profile with a 19% relative reduction in the overall incidence of adverse events versus vancomycin/cephalexin in the second and larger pivotal trial

History

Originally discovered and developed by Eli Lilly, oritavancin was acquired by InterMune in 2001 and then by Targanta Therapeutics in late 2005 In December 2008, the US Food and Drug Administration declined to approve oritavancin without additional studies, and an EU application was withdrawn

In 2009, The Medicines Company acquired the development rights, completed clinical trials and submitted a new drug application to the FDA in February 2014 On August 6, 2014, the United States FDA approved oritavancin to treat skin infections

A marketing authorisation valid throughout the European Union was granted on 19 March 2015 for the treatment of acute bacterial skin and skin structure infections in adults

References

  1. ^ Domenech, Oscar; Francius, Grégory; Tulkens, Paul M; Van Bambeke, Françoise; Dufrêne, Yves; Mingeot-Leclercq, Marie-Paule 2009-09-01 "Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: Effect on membrane permeability and nanoscale lipid membrane organization" PDF Biochimica et Biophysica Acta 1788 9: 1832–1840 doi:101016/jbbamem200905003 ISSN 0006-3002 PMID 19450541 
  2. ^ News Release 6 August 2014 "FDA approves Orbactiv to treat skin infections" FDA 
  3. ^ Scheinfeld, N 2007 "A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus" J Drugs Dermatol 6 4: 97–103 PMID 17373167 
  4. ^ 2007 ICAAC Posters: E-1612 “In Vitro Activity Profile of Oritavancin against a Broad Spectrum of Aerobic and Anaerobic Bacterial Pathogens”/E -1613 “In Vitro Activity Profile of Oritavancin ORI Against Organisms Demonstrating Key Resistance Profiles to Other Antimicrobial Agents”/E-1614 “In vitro Time Kill Studies of Oritavancin against Drug-resistant Isolates of Staphylococcus aureus and Enterococci”/E-1615 “Anti-Enterococcal Activity Profile of Oritavancin, a Potent Lipoglycopeptide under Development for Use Against Gram-Positive Infections”/E-1616 “Anti-Streptococcal Activity Profile of Oritavancin, a Potent Lipoglycopeptide under Development for Use Against Gram-Positive Infections”/E-1617 “In Vitro Activity Profile of Oritavancin ORI Against Resistant Staphylococcal Populations From a Recent Surveillance Initiative”/E-1620 “Pharmacokinetic Concentrations of Oritavancin Kill Stationary-Phase and Biofilm Staphylococcus aureus In Vitro” / Targanta Press Release September 19, 2007
  5. ^ ICAAC 2007 Posters: “In Vitro Susceptibility of Genotypically Distinct Clostridium difficile Strains to Oritavancin” and “Activity of Metronidazole, Vancomycin and Oritavancin Against Epidemic Clostridium difficile Spores” / Targanta Press Release September 19, 2007
  6. ^ ASM 2007 Poster: “Efficacy of Oritavancin in a Murine Model of Bacillus anthracis Spore Inhalation Anthrax” / Targanta Press Release May 24, 2007
  7. ^ Belley; McKay, GA; Arhin, FF; Sarmiento, I; Beaulieu, S; Fadhil, I; Parr Jr, TR; Moeck, G 2010 "Oritavancin Disrupts Membrane Integrity of Staphylococcus aureus and Vancomycin-resistant Enterococci to Effect Rapid Bacterial Killing" Antimicrobial Agents and Chemotherapy 54 12: 5369–71 doi:101128/AAC00760-10 PMC 2981232  PMID 20876372 
  8. ^ Zhanel; et al 2012 "Oritavancin: Mechanism of Action" Clin Infect Dis 54: S214–S219 doi:101093/cid/cir920 
  9. ^ ICAAC 2003 Late-breaker poster: "Phase III Trial Comparing 3–7 days of Oritavancin vs 10–14 days of Vancomycin/Cephalexin in the Treatment of Patients with Complicated Skin and Skin Structure Infections cSSSI" / InterMune Press Release September 15, 2003
  10. ^ Tomoko Okudaira 2014-05-09 "The Daily Biopharmaceutical News Source" BioWorld Retrieved 2014-06-06 
  11. ^ "Biotechs pick up slack in antibiotics development" 17 May 2011 
  12. ^ News Release 6 August 2014 "FDA approves Orbactiv to treat skin infections" FDA 
  13. ^ http://wwwemaeuropaeu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/003785/WC500186346pdf

External links

  • CARYN RABIN, RONI June 4, 2014 "Single Dose of Antibiotic Found Effective in Quelling MRSA" The New York Times Retrieved June 2014  Check date values in: |access-date= help

oritavancin, oritavancin antibiotic, oritavancin cost, oritavancin dosing, oritavancin mechanism of action, oritavancin medicines company, oritavancin osteomyelitis, oritavancin package insert, oritavancin price, oritavancin structure


Oritavancin Information about

Oritavancin


  • user icon

    Oritavancin beatiful post thanks!

    29.10.2014


Oritavancin
Oritavancin
Oritavancin viewing the topic.
Oritavancin what, Oritavancin who, Oritavancin explanation

There are excerpts from wikipedia on this article and video

Random Posts

Ralph Neville, 2nd Earl of Westmorland

Ralph Neville, 2nd Earl of Westmorland

Ralph Neville, 2nd Earl of Westmorland 4 April 1406 – 3 November 1484 was an English peer Content...
Mamprusi language

Mamprusi language

The Mamprusi language, Mampruli Mampelle, Ŋmampulli, is a Gur language spoken in northern Ghana by t...
Singapore Changi Airport

Singapore Changi Airport

Singapore Changi Airport IATA: SIN, ICAO: WSSS, or simply Changi Airport, is the primary civili...
Christian Siriano

Christian Siriano

Christian Siriano born November 18, 1985 is an American fashion designer and member of the Council o...